Compare ArcelorMittal SA (MT) vs Novavax Inc (NVAX) Price & Performance

ArcelorMittal (MT) trades at $73.90, up 0.83% with bullish technical signals and strong institutional support. The stock shows improving fundamentals with Q2 2026 revenue growth despite an earnings miss, while maintaining stable dividends. Recent news highlights strategic partnerships and European business recovery prospects.

Outlook remains cautiously optimistic with 50% analyst buy ratings, though risks include cyclical steel demand and margin pressures. The current P/E of 30.97 appears elevated relative to historical norms, requiring sustained earnings growth to justify valuation.

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.